CTH 121
Alternative Names: CTH-121Latest Information Update: 31 Mar 2023
At a glance
- Originator Connecta Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fragile X syndrome
Most Recent Events
- 28 Mar 2023 Preclinical trials in Fragile X syndrome in Spain (unspecified route) (Connecta Therapeutics pipeline, March 2023)